Uric acid and liver scarring in people with obesity
Part of Digestive system clinical trials.
This study looks at whether higher uric acid levels in the blood are linked to liver scarring (fibrosis) in people with obesity. If you qualify, you may help doctors understand how to detect liver problems earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- Your body mass index (BMI) is 30 or higher
- A blood test shows high uric acid levels (higher than 7 for men, higher than 6 for women)
- You do not drink more than 2 alcoholic drinks a day (or more than 1 for women)
- You do not have hepatitis B, other active liver diseases, or cirrhosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who are metabolically healthy but overweight or obese, and how that affects their risk of developing fatty liver disease (MASLD) or high uric acid levels (hyperuricemia). It aims to see if 'healthy' obesity still carries hidden health risks.
This study looks at whether simple blood tests can help predict liver scarring (fibrosis) in people with fatty liver disease. If you join, you'll have a quick, non-invasive scan of your liver to check for fat and scarring.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study aims to develop better ways to measure how much fibrosis (scarring) in the liver improves after treatment for NASH (fatty liver with inflammation). If you have moderate to severe liver scarring from NASH, this research could help doctors track your condition more precisely, which may lead to more effective care.
Hear when a new Hyperuricemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.